• image01
  • image02
  • image03
  • image04
  • image05
  • image06
  • image07
  • image08
  • image09
  • image10
  • image11
1947 Apri Hiroshi Tsuzuki (CEO) established the company in Tennoji-ku, Osaka with start-up capital of 195,000 yen.  1947 画像
July Injection Product for Neutropenia, "PANILTIN", sales launched
1949 February Reishin Tanimura became the President.
September Company head office relocated to Higashi-ku, Osaka.
Manufacturing plant relocated to Ashiya-shi, Hyogo.
1951 June Agreement for the sole distribution of Senju Products through Takeda Pharmaceutical Company Limited.
1955 December Masao Yoshida became the President.
1958 December Ophthalmic Solution for Cataract, "KATALIN", sales launched.  1958 画像
1962 December Itami Plant established for manufacturing of ingredients in Itami, Hyogo. 1962 画像
1965 April Artificial Tear Ophthalmic Solution, "MYTEAR", sales launched. 1965 画像
May Company head office relocated to Kita-ku, Osaka
1972 March Company head office and Osaka branch are relocated to Hiranomachi, Higashi-ku, Osaka 1972 画像
1974 June Fukusaki Plant for manufacturing established in Kanzaki-gun, Hyogo 1974 画像
June Shoji Yoshida became the President.
1978 November Company head office relocated in Hiranomachi, Higashi-ku, Osaka.
1980 February Ophthalmic Solution for exclusive use on contact lens, "MYTEAR CL", sales launched 1980 画像
1981 September Penicillin Antibiotic Ophthalmic Product, "SULPELIN", sales launched 1981 画像
1985 December Antifungal Ophthalmic Product, "PIMARICIN", sales launched
1987 January Intraocular Irrigating Solution, "OPEGUARD MA",sales launched.
1988 February Cephalosporin Antibiotic Ophthalmic Product, "BESTRON", sales launched 1988 February 画像
October NSAID Ophthalmic Solution, "NIFLAN", sales launched 1988 October 画像
1993 January Established resident office in Los Angels, California
February Established Kobe Creative Center 1993 画像
July Ophthalmic Viscoelastic Preparation, "OPELEAD", sales launched
1997 April Celebrated 50th anniversary of company foundation.
2000 July NSAID Ophthalmic Solution, "BRONUCK", sales launched 2000年画像
2001 April Established the new laboratory in Oregon, USA
2004 May Established resident office in Amsterdam, Netherland 2004 画像
September Anti-infective Fluoroquinolone Ophthalmic Solution, "GATIFLO", sales launched
2006 April Established Senju U.S.A. INC.
Established resident office in China, Beijing
June Yukoh Yoshida became the President.
2008 May Senju Medical Consulting (Shanghai) co., Ltd established in Shanghai, China.
Ophthalmic Suspension for Spring Catarrh, "TALYMUS", sales launched 2008 May 画像
December Karatsu Plant for manufacturing established in karatsu-shi, Saga 2008 December 画像
2009 October "LUMIGAN" Ophthalmic Solution 0.03% for treatment of glaucoma and ocular hypertension, sales launched. 2009年 画像
2010 November Established Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd. in Beijing, China, followed by liquidation in July 2011 of Senju Medical Consulting (Shanghai) Co., Ltd.
2011 November Established Hanoi Office in Hanoi, Vietnam.
2012 May "AIPHAGAN" Ophthalmic Solution 0.1% for treatment of glaucoma and ocular hypertension, sales launched. 2012年画像
December Established Moscow Office in Moscow, Russia.
2017 April Celebrated 70th anniversary of company foundation.
2018 February Completed construction of new corporate building. 2018年画像
June "IBULIEF" I.V. Injection 20 mg for treatment of patent ductus arteriosus in premature infants, sales launched.
2019 April Established Kobe Innovative Center. 2019年画像
June Shuhei Yoshida became President.
September Macrolide antibiotic "AZIMYCIN" Ophthalmic Solution 1% sales launched. 2019年画像
December "AIBETA" Combination Ophthalmic Solution for treatment of glaucoma and ocular hypertension, sales launched. 2020年画像
2020 June "AILAMIDE" Combination Ophthalmic Suspension for treatment of glaucoma and ocular hypertension, sales launched. 2020年画像
2021 December “Ranibizumab BS Intravitreal Injection Kit 10 mg/mL ‘Senju’” for treatment of nAMD and mCNV, sales launched. 2021年画像